Evidence map›Paper›PMID 38659032›Full record

ArticleIsrael journal of health policy research2024

Pfizer COVID19 vaccine is not associated with acute cardiovascular events excluding myocarditis- a national self-controlled case series study.

Lital Keinan Boker, Ronen Fluss, Rita Dichtiar, Alina Rosenberg, Maya Ben-Lassan, Amit Huppert

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Israel journal of health policy research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lital Keinan Boker *Israel Center for Disease Control, Ministry of Health, Sheba Medical Center, Gertner bldg, 52621, Tel Hashomer, Ramat Gan, Israel. Lital.keinan2@moh.gov.il.
Ronen Fluss *Gertner Institute for the Study of Epidemiology and Health Policy, Sheba Medical Center, Ramat Gan, Israel.
Rita DichtiarIsrael Center for Disease Control, Ministry of Health, Sheba Medical Center, Gertner bldg, 52621, Tel Hashomer, Ramat Gan, Israel.
Alina RosenbergIsrael Center for Disease Control, Ministry of Health, Sheba Medical Center, Gertner bldg, 52621, Tel Hashomer, Ramat Gan, Israel.
Maya Ben-LassanIsrael Center for Disease Control, Ministry of Health, Sheba Medical Center, Gertner bldg, 52621, Tel Hashomer, Ramat Gan, Israel.
Amit HuppertGertner Institute for the Study of Epidemiology and Health Policy, Sheba Medical Center, Ramat Gan, Israel.
Sheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite publications assuring no increased risk for acute cardiovascular events (excluding myocarditis) and sudden death following administration of COVID19 vaccines, these issues still stir much public ado. We assessed the risk for acute cardiovascular events that require hospitalization (excluding myocarditis) and for mortality in the short-term following administration of the second dose of the Pfizer COVID19 vaccine in Israel.

methodsUsing a self-controlled case series (SCCS) study design and national databases, all second-dose vaccinees, who had not been diagnosed with COVID19 and who had an acute cardiovascular event (acute myocardial infarction/acute stroke/acute thromboembolic event) that required hospitalization in the 60 days following vaccine administration between Jan 11th, 2021 and Oct 31st 2021, were included. A similar analysis was carried out for mortality. The first 30 days following vaccination were defined as risk period while the next 30 days were defined as control period. The probability for an event between these periods was compared using a conditional logistic regression model, accounting for sex, age group, background morbidity and seasonal risk.

resultsOut of 5,700,112  second dose vaccinees, 4,163 had an acute cardiovascular event in the 60 days following vaccine administration. Following exclusion of 106 due to technical considerations, 1,979 events occurred during the risk period and 2,078 during the control period: Odds ratio, OR = 0.95, 95% confidence interval, CI 0.90-1.01, p = 0.12. Adjusted OR was similar (OR = 0.88, 95%CI 0.72-1.08). Stratifying by age showed no increased risk in any age group. Mortality assessment indicated low number of events in both periods. These results were consistent in sensitivity analyses.

conclusionsThere was no increased risk for acute cardiovascular events (excluding myocarditis) in the risk period compared to the control period following administration of the second dose of Pfizer COVID19 vaccine. Mortality data raised no concerns either, but may have been biased.

Indexed as

Cardiovascular DiseasesCOVID-19AdultAgedBNT162 VaccineCase-Control StudiesCOVID-19 VaccinesFemaleHospitalizationHumansIsraelMaleMiddle AgedMyocardial InfarctionMyocarditisBNT162 VaccineCOVID-19 VaccinesAcute cardiovascular eventsIsraelPfizer COVID19 vaccineSelf-controlled case series

Identifiers

PMID38659032
PMCPMC11040923
OpenAlexW4395075600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.